Page last updated: 2024-11-06
chaulmoogric acid
Description
chaulmoogric acid: component of CHAULMOOGRA OIL; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(R)-chaulmoogric acid : The (R)-enantiomer of chaulmoogric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
chaulmoogric acid : A monounsaturated long-chain fatty acid composed of tridecanoic acid having a 2-cyclopentenyl substituent at the 13-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 12302887 |
CHEBI ID | 61389 |
SCHEMBL ID | 560850 |
MeSH ID | M0067600 |
Synonyms (19)
Synonym |
2-cyclopentene-1-tridecanoic acid |
chaulmoogric acid |
(r)-13-(cyclopent-2-en-1-yl)tridecanoic acid |
(r)-2-cyclopentene-1-tridecanoic acid |
(r)-chaulmoogric acid |
13-[(r)-cyclopent-2-enyl]-tridecansauere |
13-[(1r)-cyclopent-2-en-1-yl]tridecanoic acid |
(+)-chaulmoograsauere |
13-(r)-cyclopent-2-enyl-tridecansaeure |
acido (r)-chaulmogrico |
CHEBI:61389 |
13-(r)-cyclopent-2-enyl-tridecanoic acid |
acide (r)-chaulmoogrique |
13-[(r)-cyclopent-2-enyl]-tridecanoic acid |
LMFA01140017 |
13-(2-cyclopenten-1-yl)tridecanoic acid |
13r-(2-cyclopentenyl)-tridecanoic acid |
13-(cyclopent-2-enyl)-n-tridecanoic acid |
SCHEMBL560850 |
Drug Classes (1)
Class | Description |
chaulmoogric acid | A monounsaturated long-chain fatty acid composed of tridecanoic acid having a 2-cyclopentenyl substituent at the 13-position. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |